Stockscreener 앱 받기
0.51
8.93%
-0.05
시간 외 거래:
.50
-0.01
-1.96%
전일 마감가:
$0.56
열려 있는:
$0.541
하루 거래량:
722.80K
Relative Volume:
1.46
시가총액:
$17.04M
수익:
-
순이익/손실:
$-19.73M
주가수익비율:
-0.2459
EPS:
-2.0742
순현금흐름:
$-16.94M
1주 성능:
-12.07%
1개월 성능:
-34.62%
6개월 성능:
-55.26%
1년 성능:
-34.18%
1일 변동 폭
$0.4901
$0.5609
1주일 범위
$0.4901
$0.6121
52주 변동 폭
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
명칭
Pasithea Therapeutics Corp
전화
(702) 514-4174
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.51 | 18.71M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times
Pasithea Therapeutics (KTTA) could find a support soon, here's why you should buy the stock now - MSN
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEPS Consistency Score - newsline.com
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Operational Efficiency ImprovesUpward Estimate Revision - newsline.com
PASITHEA THERAPEUTICS CORP (KTTA) Stock Chart - ChartMill
Why Is Pasithea Therapeutics Corp. (KTTAW) Stock Down Today? - Meyka
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis - Investing News Network
Pasithea receives orphan drug status for ALS treatment candidate - Investing.com
Pasithea receives orphan drug status for ALS treatment candidate By Investing.com - Investing.com South Africa
FDA grants rare-disease status to Pasithea ALS drug PAS-004 - Stock Titan
Pasithea Therapeutics (KTTA) Slips 3% as Shares Test Key Support Near $0.64Bollinger Squeeze - newsline.com
KTTA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Surprise History - The Legal Advocate
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Sahm
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Significant EPS Beat Despite Zero RevenueHigh Interest Stocks - Newser
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock SlipsPost-Announcement Reaction - thelegaladvocate.com
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained - TipRanks
Pasithea Therapeutics (KTTA) Stalls at $0.78 — Breakout or Breakdown? 2026-05-18Collar Trade - newsline.com
Pasithea Therapeutics Corp.Common Stock (NQ: KTTA - The Chronicle-Journal
Pasithea Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. 1Q 2026: Net loss $(2.87M), EPS $(0.12) — 10-Q Summary - TradingView
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pasithea Therapeutics (NASDAQ: KTTA) ramps PAS-004 R&D on $50M cash base - Stock Titan
Ameriprise (KTTA) reports 1.35M-share, 5.4% stake in Pasithea Therapeutics - Stock Titan
TradingKey - TradingKey
Pasithea Therapeutics appoints chief medical officer - MSN
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
8-K: Current report - Moomoo
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Pasithea Therapeutics Corp (KTTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
1.27%
1.43%
자본화:
|
볼륨(24시간):